The rapid growth of GLP-1 receptor agonists, dual agonists and other emerging therapies is accelerating drug development across obesity and type 2 diabetes. At the same time, sponsors face increasing pressure to demonstrate more than just weight loss or glycemic control. This webinar will explore how phase-appropriate endpoint strategies can support stronger development decisions and more differentiated evidence across obesity clinical trials.
Development teams increasingly need to understand how a therapy affects the whole patient, including symptoms, treatment experience, glucose patterns, body composition, organ health and cardiovascular safety. However, the questions sponsors need to confidently answer in early-phase trials differ from those addressed in larger Phase II and Phase III programs.
Join the featured experts in eCOA, cardiac safety and medical imaging to learn how phase-appropriate endpoint solutions that generate high-quality, informative data can support critical decisions. From detecting early safety and efficacy signals informing dose selection, go/no-go and study design decisions, to characterizing treatment benefit and risk building a differentiated, regulator-ready evidence package, implementing the right endpoint strategy and technologies is paramount.
Register to learn how an integrated, phase-appropriate endpoint strategy can help teams identify meaningful signals earlier, reduce development uncertainty and generate stronger evidence for regulatory review and product differentiation.
Who Should Attend
This webinar will benefit professionals in the following fields with the following job titles:
CEOs/Chief Medical Officers/Chief Scientific Officers
Clinical Data Managers/Clinical IT/Clinical Monitoring
Clinical Operations/Clinical Development (early phase)
Clinical Research/Clinical Pharmacologists/Clinical Scientists
Data Science
Digital Health/Innovations/Operations
Health Economics and Outcomes Research
Imaging Scientists/Medical Affairs/Medical Monitor/Head of Development for Program
Neuroscience Clinical Trials Professionals
PK Experts/Protocol Managers/Regulatory Affairs
Professionals in the field of Multiple Sclerosis
Sr. Managers, Trial Initiation
What You Will Learn
By attending this webinar, attendees will learn how to:
Build a phase-appropriate endpoint strategy that integrates patient-reported outcomes, glucose monitoring technologies (BGM & CGM), cardiac and imaging data to support the critical decisions required across the development cycle
Connect the subjective patient experience with objective glucose data by studying symptoms, medication timing, fasting status, rescue actions and connected glucose readings. Attendees will also learn how this data can reveal early safety, tolerability and efficacy signals, inform dose selection and study design and strengthen the late-phase treatment-benefit narrative
Evolve cardiac safety assessments across development, from focused QTc and heart-rate evaluation in early safety trials to consistent, scalable collection of 12-lead ECG and blood-pressure data in later development
Select the right imaging strategy for Phase II and Phase III trials evaluating obesity, body composition analysis, impact on fatty liver disease and the broader physiological effects of weight-loss therapies
Generate differentiating evidence beyond the standard body weight and glycemic control measures leveraging innovation modalities such as MRI-PDFF, MR elastography, organ volumetry, visceral and subcutaneous adipose tissue analysis and functional MRI
Register free on Xtalks:
https://xtalks.com/webinars/optimize-obesity-development-endpoint-strategies-for-early-phase-innovation-to-late-phase-differentiation/
